Table 4.
Performance assessment of C2Maps in varying cancers.
| Bladder | Breast | Leukemia | Lung | Lymphoma | Melanoma | Ovary | Pancreas | Prostate | |
|---|---|---|---|---|---|---|---|---|---|
| Sensitivity | 80.84% | 79.80% | 83.16% | 78.44% | 81.20% | 77.39% | 80.88% | 84.99% | 82.84% |
| Specificity | 87.11% | 84.91% | 86.11% | 89.37% | 87.60% | 91.53% | 84.34% | 86.45% | 88.38% |
| ACC | 86.70% | 84.27% | 85.63% | 87.86% | 86.78% | 90.17% | 84.09% | 86.34% | 87.93% |
| PPV | 30.51% | 43.01% | 53.39% | 54.06% | 48.92% | 49.24% | 28.84% | 33.82% | 38.88% |
| F-Score | 44.30% | 55.89% | 65.03% | 64.01% | 61.05% | 60.19% | 42.52% | 48.38% | 52.92% |
The experiment were performed using a protein interaction confidence minimum threshold of 3 star and above (i.e., reliability score of >0.75) and retrieved drug p-value at a minimum threshold of 0.05. The detailed evaluation procedures and measurement definitions, they can be found in the "Method FAQ" page of our C2Maps website and as supplemental materials.